Skip to main content

Imbruvica 140mg capsules | Ibrutinib | MHP

    IMBRUVICA 140MG




DESCRIPTION


Imbruvica 140mg is a targeted drug aim to destroy the type of cell which has converted into cancerous orends signals which make cancerous cells develop or multiply. In lymphoma, the type of cell which becomes cancerous is called a ‘lymphocyte’ (a type of white blood cell that fights infection). There are different types of lymphocyte which can become cancerous.
Imbruvica 140mg attacks B lymphocytes (B cells) and is therefore necessary to treat B-cell lymphomas.


Imbruvica 140 mg capsule
Imbruvica 140 mg


INDICATION


Imbruvica 140mg is an antineoplastic drug which is:
• Indicated for the treatment of Chronic lymphocytic leukaemia or small lymphocytic lymphoma
• Indicated for the treatment of Mantle cell lymphoma
• Indicated for the treatment of Waldenström Macroglobulinemia
• Indicated for the treatment of Marginal Zone lymphoma
• Indicated for the treatment of Graft vs Host Disease

MECHANISM OF ACTION

Ibrutinib prohibits the Bruton's tyrosine kinase (BTK)function. BTK is a basic signaling molecule of the B-cell receptor signaling complex which plays an important role in the endurance of malignant B cells.

Ibrutinib stops signals whichprompt malignant B cells to develop and multiply uncontrollably.

ADME

Absorption:
Time to peak plasma concentration of Imbruvica is 1-2 hours and drug taking with food will increases ibrutinib exposure.
Distribution:
Human plasma protein level is 97.3% and Vd is 10,000L
Metabolism:
Metabolized to several metabolites mainly by cytochrome P450 CYP3A, and to a minor extent by CYP2D6
Elimination:
Imbruvica was excretion via feces 80% and urine 10 %
Half-life of Imbruvica is 4-6 hours

DOSAGE MANAGEMENT

Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma :
The usual dose of imbruvicais 420mg given three 140mg capsules per oral qDay
While in concomitant use with bendamustine and rituximab the prescribed dose is 420mg PO qDay administrated q28d for up to 6 cycles until progression or undesirable toxicity
Mantle Cell Lymphoma :
The usualdose of imbruvica is 560mg given four 140mg-mg capsules PO qDay.
Extend until disease progression or undesirable toxicity
Waldenström Macroglobulinemia :
The usualdose of imbruvicais 420mg given three 140mg capsules per oral qDay
When concomitant use with rituximab is 420 mg PO qDay plus rituximab administered weekly for 4 consecutive weeks (weeks 1-4) continued by a second course of weekly rituximab for 4 consecutive weeks (weeks 17-20)
Marginal Zone Lymphoma :
The usualdose of imbruvica is 560mg given four 140mg-mg capsules PO qDay.
Extend until disease progression or undesirable toxicity
Graft vs Host Disease :
The usualdose of imbruvicais 420mg given three 140mg capsules per oral qDay
Extenduntil cGVHD development, relapsed of an underlying malignancy, or undesirable toxicity occurs

PRECAUTIONS:

• While on treatment with Imbruvica 140mg capsule Hypertension occurs with a median time to onset of 4.6 months; regulate for new onset hypertension or hypertension that is not enough controlled after starting ibrutinib
• While on treatment with Imbruvica 140mg capsule, Tumor lysis syndrome intermittently resulted; assess the baseline risk (e.g., high tumor burden) and take suitable precautions
• While on treatment with Imbruvica 140mg capsule Other malignancies (5-14%) resulted contains carcinomas (1-3%); the most frequent second primary malignancy was nonmelanoma skin cancer (4-11%)
• When administered to a pregnant woman,based on findings in animals, can cause fetal risk
• While on treatment with Imbruvica 140mg, lethal and severe cases of renal failure reported.


SIDE EFFECTS:

More common side effects of Imbruvica 140mg :
Fever, Stomatitis, Dizziness, Urinary Tract Infection, Pneumonia, Dyspepsia, Petechiae, Arthralgia, Nosebleeds, Skin infections, Asthenia, Muscle spasms, Shortness of breath, Constipation, Rash, Sinusitis, Headache, Dehydration, Abdominal pain, Vomiting, Decreased appetite, Cough.
More common side effects of Imbruvica 140mg :
Reduced neutrophils, Decreased haemoglobin, Fatigue, Bruising, Thrombocytopenia, Musculoskeletal pain, Swelling, Upper respiratory tract infection, Nausea, Diarrhea.


FOR MORE INFORMATION:


PHONE NO : +91-9940472902
EMAIL :millionhealthpharmaceuticals@gmail.com
Website address:https://millionpharma.com/imbruvica-140mg.php
Labels:

Comments

Post a Comment

Popular posts from this blog

Stivarga 40mg Tablets| Regorafenib Uses & Side effects

STIVARGA 40MG DESCRIPTION Stivarga 40mg consist of protein kinase inhibitor with a similar structure to sorafenib. It is hoping to act by prohibiting multiple signalling pathways contains in angiogenesis and tumour growth. Stivarga 40mg is commonly given after other chemotherapy have been tried without success. Stivarga 40mg which is used as prescription drugs under the supervision of medical practioners. INDICATION: Stivarga 40mg is an anticancer drug which is; Indicated for the treatment of Hepatocellular carcinoma Indicated for the treatment of Colorectal cancer Indicated for the treatment of Gastrointestinal stromal tumor MECHANISM OF ACTION: Regorafenib consist of systemic therapy which works throughout your body to promote fight certain cancers. Regorafenib belongs to a multikinase inhibitor, may work by stopping some proteins on certain normal and cancer cells. In this way, Regorafenib may inhibit cancers from growing and spreading for a period. Can...
Post a Comment
Read more

Tagrisso 40mg Tablets| Osimeritinib Uses & Side effects

                                                   TAGRISSO 40MG DESCRIPTION A Tagrisso 40mg tablet is containing an active substance known as Osimeritinib, which is formerly known as Mereletinib. Tagrisso 40mg is considered as third generation medicine, which is available in tablet form. Tagrisso 40mg tablet is an inevitable, selectively deviated epidermal growth factor receptor prohibitor, containing anti-cancer activity. The pharmacological category of Tagrisso 40mg is tyrosine kinase prohibitor. INDICATION: A T agrisso 40mg tablet is widely indicated as first line therapy for advanced non-small cell lung cancer with EGFR mutation positive patients.Tagrisso 40mg is also used for the treatment of patients affected with advanced EGFR T792M mutation positive NSCLC, disease has advanced on or after the tyrosine kinase inhibitor treatment. M...
Post a Comment
Read more

Lynparza 50mg capsules | Olaparib | Millionpharma

                                    LYNPARZA 50MG DESCRIPTION Olaparib is a generic form of brand name Lynparza 50 mg . Which is required for some types of ovarian cancer that have come back after treatment. It is for people whohave a alter in a gene called BRCA and have had a variety of chemotherapy called platinum Lynparza 50 mg which used asprescription drug which used under the supervision of medical practioners Lynparza 50 mg INDICATION: Lynparza 50 mg tablet is an antitumor medication which is Indicated for the treatment in patients with advanced ovarian cancer Indicated for the treatment in patients with HER2 – negative metastatic breast cancer. MECHANISM OF ACTION: Olaparib belongs to poly (ADP-ribose) polymerase (PARP) enzyme inhibitor, containing PARP1, PARP2, and PARP3. PARP enzymes are included in DNA transcription, cell cycle managing, and DNA repair. Ol...
Post a Comment
Read more